Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine

Shifeng Wang, Yuhua Li, Huoying Shi, Giorgio Scarpellini, Ascencion Torres-Escobar, Kenneth L. Roland, Roy Curtiss

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Streptococcus pneumoniae is a leading cause of morbidity and mortality among children worldwide and particularly in developing countries. In this study, we evaluated PsaA, a conserved antigen important for S. pneumoniae adhesion to and invasion into nasopharynx epithelia, for its ability to induce protective immunity against S. pneumoniae challenge when delivered by recombinant attenuated Salmonella vaccine (RASVs) strains. RASVs were engineered to synthesize PsaA peptides of various lengths. Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2d) or C57BL/6 (haplotype H2b) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3). Immunization with RASVs synthesizing truncated PsaA generated lower titers of IgA and IgG and did not provide significant protection. Our results showed that RASVs synthesizing full-length PsaA can provide protection against nasal colonization by some S. pneumoniae strains. PsaA may be a useful addition to a multivalent vaccine, providing protection against pneumonia, otitis media, and other diseases caused by S. pneumoniae.

Original languageEnglish (US)
Pages (from-to)3258-3271
Number of pages14
JournalInfection and Immunity
Volume78
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Salmonella Vaccines
Attenuated Vaccines
Streptococcus pneumoniae
Synthetic Vaccines
Antigens
Nose
Immunoglobulin A
Vaccines
Immunoglobulin G
Child Mortality
Nasopharynx
Otitis Media
Inbred C57BL Mouse
Haplotypes
Developing Countries
Anti-Idiotypic Antibodies
Immunity
Immunization
Pneumonia
Vaccination

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Parasitology
  • Infectious Diseases

Cite this

Wang, S., Li, Y., Shi, H., Scarpellini, G., Torres-Escobar, A., Roland, K. L., & Curtiss, R. (2010). Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infection and Immunity, 78(7), 3258-3271. https://doi.org/10.1128/IAI.00176-10

Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. / Wang, Shifeng; Li, Yuhua; Shi, Huoying; Scarpellini, Giorgio; Torres-Escobar, Ascencion; Roland, Kenneth L.; Curtiss, Roy.

In: Infection and Immunity, Vol. 78, No. 7, 07.2010, p. 3258-3271.

Research output: Contribution to journalArticle

Wang, S, Li, Y, Shi, H, Scarpellini, G, Torres-Escobar, A, Roland, KL & Curtiss, R 2010, 'Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine', Infection and Immunity, vol. 78, no. 7, pp. 3258-3271. https://doi.org/10.1128/IAI.00176-10
Wang, Shifeng ; Li, Yuhua ; Shi, Huoying ; Scarpellini, Giorgio ; Torres-Escobar, Ascencion ; Roland, Kenneth L. ; Curtiss, Roy. / Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. In: Infection and Immunity. 2010 ; Vol. 78, No. 7. pp. 3258-3271.
@article{1ff5db02a41148e1bb7384e3fd22ad6b,
title = "Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine",
abstract = "Streptococcus pneumoniae is a leading cause of morbidity and mortality among children worldwide and particularly in developing countries. In this study, we evaluated PsaA, a conserved antigen important for S. pneumoniae adhesion to and invasion into nasopharynx epithelia, for its ability to induce protective immunity against S. pneumoniae challenge when delivered by recombinant attenuated Salmonella vaccine (RASVs) strains. RASVs were engineered to synthesize PsaA peptides of various lengths. Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2d) or C57BL/6 (haplotype H2b) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3). Immunization with RASVs synthesizing truncated PsaA generated lower titers of IgA and IgG and did not provide significant protection. Our results showed that RASVs synthesizing full-length PsaA can provide protection against nasal colonization by some S. pneumoniae strains. PsaA may be a useful addition to a multivalent vaccine, providing protection against pneumonia, otitis media, and other diseases caused by S. pneumoniae.",
author = "Shifeng Wang and Yuhua Li and Huoying Shi and Giorgio Scarpellini and Ascencion Torres-Escobar and Roland, {Kenneth L.} and Roy Curtiss",
year = "2010",
month = "7",
doi = "10.1128/IAI.00176-10",
language = "English (US)",
volume = "78",
pages = "3258--3271",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine

AU - Wang, Shifeng

AU - Li, Yuhua

AU - Shi, Huoying

AU - Scarpellini, Giorgio

AU - Torres-Escobar, Ascencion

AU - Roland, Kenneth L.

AU - Curtiss, Roy

PY - 2010/7

Y1 - 2010/7

N2 - Streptococcus pneumoniae is a leading cause of morbidity and mortality among children worldwide and particularly in developing countries. In this study, we evaluated PsaA, a conserved antigen important for S. pneumoniae adhesion to and invasion into nasopharynx epithelia, for its ability to induce protective immunity against S. pneumoniae challenge when delivered by recombinant attenuated Salmonella vaccine (RASVs) strains. RASVs were engineered to synthesize PsaA peptides of various lengths. Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2d) or C57BL/6 (haplotype H2b) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3). Immunization with RASVs synthesizing truncated PsaA generated lower titers of IgA and IgG and did not provide significant protection. Our results showed that RASVs synthesizing full-length PsaA can provide protection against nasal colonization by some S. pneumoniae strains. PsaA may be a useful addition to a multivalent vaccine, providing protection against pneumonia, otitis media, and other diseases caused by S. pneumoniae.

AB - Streptococcus pneumoniae is a leading cause of morbidity and mortality among children worldwide and particularly in developing countries. In this study, we evaluated PsaA, a conserved antigen important for S. pneumoniae adhesion to and invasion into nasopharynx epithelia, for its ability to induce protective immunity against S. pneumoniae challenge when delivered by recombinant attenuated Salmonella vaccine (RASVs) strains. RASVs were engineered to synthesize PsaA peptides of various lengths. Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2d) or C57BL/6 (haplotype H2b) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3). Immunization with RASVs synthesizing truncated PsaA generated lower titers of IgA and IgG and did not provide significant protection. Our results showed that RASVs synthesizing full-length PsaA can provide protection against nasal colonization by some S. pneumoniae strains. PsaA may be a useful addition to a multivalent vaccine, providing protection against pneumonia, otitis media, and other diseases caused by S. pneumoniae.

UR - http://www.scopus.com/inward/record.url?scp=77953934041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953934041&partnerID=8YFLogxK

U2 - 10.1128/IAI.00176-10

DO - 10.1128/IAI.00176-10

M3 - Article

VL - 78

SP - 3258

EP - 3271

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 7

ER -